New heart ablation tool tested in humans for first time
NCT ID NCT07503769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new catheter that uses two types of energy (radiofrequency and pulsed field) to treat rapid heartbeats from the lower chambers. Ten adults with drug-resistant ventricular arrhythmias will receive the procedure. The main goal is to check safety and see if the abnormal rhythm stops right after treatment and at 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dual-energy ablation catheter (radiofrequency and pulsed field)
What this could lead to
If successful, this could lead to a safer, more effective way to treat abnormal heart rhythms without long-term medication.
What could go wrong
This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The procedure carries risks like bleeding, heart damage, or arrhythmia recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China